Sharemaestro Newsreel

Bionano Genomics Inc (BNGO) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Bionano Genomics Inc (BNGO), detailing its price momentum score of 3.18 and identifying current support at $1.00 and resistance at $1.16. It presents a summary of various technical indicators, such as MACD and RSI, which largely suggest …

Nyxoah SA (NYXH) Institutional Confidence

This article provides an "Institutional Confidence" score and detailed shareholder activity for Nyxoah SA (NYXH). It lists key institutional shareholders, their shareholdings, and percentage changes, with Cochlear Limited and Robert Taub holding the largest positions. The data was updated on July 31, 2026, indicating …

Pulse Biosciences to Present at Canaccord Genuity’s 46th Annual Growth Conference

Pulse Biosciences, Inc. announced its participation in Canaccord Genuity's 46th Annual Growth Conference. Management is scheduled to present on Tuesday, August 11, at 2:30 pm ET, with a live and recorded webcast available on the company's investor website. The company will discuss its Nanosecond …

Precision Optics Corporation Inc (POCI) Institutional Confidence

This article from TradingKey provides an overview of Precision Optics Corporation Inc (POCI)'s institutional confidence, detailing the score and recent changes. It lists major institutional shareholders and their shareholdings, along with percentage changes in their positions. The data is current as of July 30, …

Nephros Inc (NEPH) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis for Nephros Inc (NEPH), detailing its current valuation score, P/E ratio, and market data. It highlights that the company's valuation score is 8.25, placing it 75th in its industry, and notes its P/E ratio of 46.43. The analysis …

Merit Medical Reports Second Quarter 2026 Results And Updates Full-Year 2026 Guidance

Merit Medical Systems, Inc. announced strong financial results for the second quarter of 2026, surpassing expectations with a 9% organic, constant currency revenue growth. The company reported a 10% increase in U.S. sales and improved non-GAAP operating margin and EPS. Reflecting these robust results, …

Earnings call transcript: Merit Medical tops Q2 2026 estimates and lifts outlook

Merit Medical Systems reported strong Q2 2026 results, exceeding Wall Street expectations for profit and sales with adjusted earnings of $1.19 per share and revenue of $418.8 million. The company also raised its full-year outlook, citing its strongest organic growth in three years and …

CooperCompanies Announces Release Date for Third Quarter 2026

CooperCompanies announced it will release its third quarter 2026 financial results on Thursday, August 28, 2026, after the market closes. The company will also host a conference call and webcast to discuss the results, providing investors and interested parties with an opportunity to review …

AtriCure (ATRC) Looks Repriced As Strong Q2 Earnings And Higher Guidance Reset The Story

AtriCure (ATRC) has seen significant repricing following strong Q2 earnings, reporting US$153.6 million in revenue and US$8.96 million in net income, coupled with raised 2026 guidance. While recent stock performance has been robust, opinions diverge on its valuation, with some models suggesting it is …

Merit Medical posts Q2 beat, raises FY26 EPS and sales guidance

Merit Medical Systems exceeded its Q2 2026 expectations with $418.8 million in revenue, a 10% increase year-over-year, and non-GAAP EPS of $1.19, up 18%. This strong performance, driven by robust U.S. demand and margin expansion, led the company to raise its full-year 2026 adjusted …

SOLV|Solventum Corp|Price:85.140|Chg%:-1.680

This article provides a comprehensive stock analysis of Solventum Corp (SOLV) by TradingKey. It highlights that Solventum Corp's fundamentals are stable, with high growth potential and a fairly valued assessment within its industry. The analysis also covers institutional ownership, analyst ratings, and various financial …

AptarGroup (ATR) Tops Q2 Earnings and Revenue Estimates

AptarGroup (ATR) exceeded Q2 earnings and revenue estimates, reporting $1.42 per share against a Zacks Consensus Estimate of $1.34, and revenues of $1.03 billion, surpassing the estimate by 2.32%. The company has outperformed consensus EPS and revenue estimates in the last four quarters, with …

Do Options Traders Know Something About Alcon Stock We Don't?

Options traders are showing significant interest in Alcon Inc. (ALC) stock, with high implied volatility in the Dec 18, 2026 $37.5 Call, suggesting expectations of a major price movement. Despite this, Alcon currently holds a Zacks Rank #3 (Hold) and analysts have recently revised …

AtriCure, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:ATRC) 2026-07-30

AtriCure, Inc. (ATRC) published its Q2 2026 earnings call presentation on July 30, 2026. The company reported EPS of $0.18, beating estimates by $0.16, and revenue of $153.60 million, a 12.83% year-over-year increase, beating estimates by $1.79 million. This article provides access to the …

Baxter International Inc. Stock 12‑Month Price Target Raised to $23.1, Implies 7% Downside

The average 12-month price target for Baxter International Inc. (BAX) stock has been raised from $21.4 to $23.1 by 10 analysts, with a range of $17 to $32. Based on the July 29 closing price, this new target suggests a potential 7% downside. The …

Merit Medical Systems (NASDAQ:MMSI) Jumps After Q2 Earnings Beat and Revenue Slightly Ahead of Estimates

Merit Medical Systems (NASDAQ:MMSI) reported strong second-quarter 2026 results, with non-GAAP EPS of $1.19 significantly beating analyst estimates of $0.9782 and revenue of $418.8 million slightly exceeding projections. This performance, driven by strength in cardiovascular and endoscopy segments, led to a positive market reaction …

Baxter International 2Q EPS 24c >BAX

Baxter International reported its second-quarter earnings per share at 24 cents. This indicates the company's financial performance for the recent quarter.

(MMSI) Merit Medical Systems Now Expects Full Year 2026 Adjusted EPS Range $4.25 - $4.35, vs. FactSet Est of $4.07

Merit Medical Systems (MMSI) has updated its guidance for the full year 2026, now expecting adjusted EPS to be in the range of $4.25 - $4.35. This revised forecast is notably higher than the FactSet estimate of $4.07. The company had also previously announced …

Aptargroup reports Q2 revenue over $1.0B; adjusted EPS $1.42, adjusted EBITDA margin 20.7%

Aptargroup reported Q2 2026 revenue exceeding $1.03 billion, a 6% increase year-over-year, marking the first quarter above $1 billion. The company achieved an adjusted diluted EPS of $1.42 and an adjusted EBITDA margin of 20.7%, with growth seen across its Pharma, Beauty, and Closures …

(ATR) AptarGroup, Inc. Expects Q3 Adjusted EPS Range $1.45 - $1.53

AptarGroup, Inc. anticipates its adjusted Earnings Per Share (EPS) for the third quarter to be in the range of $1.45 to $1.53. This announcement follows their Q2 performance where adjusted earnings fell while revenue rose. The company is actively involved in share buyback plans …

AtriCure (NASDAQ: ATRC) director exercises 25,000 options and sells 25,000 shares

AtriCure director Sven Wehrwein exercised 25,000 non-qualified stock options at $19.95 per share and subsequently sold all 25,000 resulting shares at a weighted average price of $37.84 per share on July 28, 2026. Following these transactions, no options remain outstanding under this specific grant, …

AtriCure, Inc. (ATRC) insider sells 6,182 shares at $38.80

AtriCure, Inc.'s Chief Marketing & Strategy Officer, Justin J. Noznesky, sold 6,182 shares of common stock on July 29, 2026, at a weighted average price of $38.80 per share. The transaction, executed in multiple trades, resulted in Noznesky directly holding 100,219 shares of the …

Bionano Genomics (BNGO) CSO reports holding 63 shares

Bionano Genomics' Chief Scientific Officer, Alex Reid Hastie, has filed an initial statement of beneficial ownership (Form 3) reporting direct ownership of 63 shares of the company's common stock. This filing indicates no insider purchases or sales in this specific report. It establishes his …

AptarGroup: Q2 Earnings Snapshot

Baxter International Inc (BAX) (Q2 2026) Earnings Call Highlights: Strong Revenue Beat Offsets ...

Baxter International Inc. reported strong Q2 2026 results with global sales increasing 5% to approximately $3 billion, driven by robust performance across all segments. Despite a decline in adjusted EPS due to higher manufacturing costs and an ongoing hold on a key infusion pump, …

Can Align Technology (ALGN) Still Be Undervalued After Its Review?

Align Technology (ALGN) appears undervalued according to a Discounted Cash Flow (DCF) analysis, suggesting a 39.7% discount to its estimated intrinsic value. However, its P/E ratio is broadly in line with industry peers, indicating a mixed valuation picture. The company's recent strong stock recovery …

AVTR Q2 Deep Dive: Strategic Initiatives and Segment Execution Drive Guidance Increase

AVTR Q2 Deep Dive: Strategic Initiatives and Segment Execution Drive Guidance Increase Life sciences company Avantor (NYSE:AVTR) beat Wall Street's revenue expectations in Q2 CY2026, but sales were flat year on year at $1.69 billion. Its non-GAAP profit of $0.21 per share was 11% …

Align Technology Announces Board Changes and Strategic Review

Align Technology announced several corporate initiatives, including the appointment of three independent directors to its board and an increased share repurchase commitment, following discussions with activist investor Elliott Investment Management. These changes aim to strengthen commercial execution, enhance organizational effectiveness, and optimize resources. The …

Merit Medical Systems (NASDAQ: MMSI) Q2 earnings rise on margin gains

Merit Medical Systems reported a strong Q2 2026, with net sales increasing by 9.5% to $418.8 million and net income rising to $38.8 million, or $0.65 diluted EPS, driven by improved gross profit margins. The company's foundational and therapeutic product categories both saw significant …

Kestra Medical Technologies (KMTS) plans sale of 7,857 shares from equity award

Kestra Medical Technologies (KMTS) has disclosed a planned sale of 7,857 common shares through Merrill Lynch on July 30, 2026. These shares originated from a performance stock issuance on July 17, 2026, under an equity compensation plan. The filing also notes recent sales over …

Kestra Medical Technologies (KMTS) plans sale of 5,887 vested shares

Kestra Medical Technologies (KMTS) has filed notice to sell 5,887 shares of common stock through Merrill Lynch on or about July 30, 2026. These shares, with an aggregate market value of $133,892.22, stem from the vesting of performance share unit awards on July 17, …

Kestra Medical Technologies (KMTS) holder to resell 5,936 vested shares

A security holder of Kestra Medical Technologies (KMTS) plans to resell 5,936 shares of common stock through Merrill Lynch on or after July 30, 2026, on NASDAQ. These shares, valued at approximately $135,120.73, originated from the vesting of performance share unit awards on July …

(ICUI) and the Role of Price-Sensitive Allocations

This article provides an AI-driven analysis of Icu Medical Inc. (NASDAQ: ICUI), highlighting strong near and mid-term sentiment and the absence of overhead resistance, suggesting upside potential. It presents three institutional trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis, including …

CooperCompanies schedules Sept. 9 results call at 5 p.m. ET

CooperCompanies (Nasdaq: COO) announced it will release its third quarter 2026 financial results on Wednesday, September 9, 2026, at 4:15 PM ET, followed by a conference call at 5:00 PM ET to discuss the results and current corporate developments. A webcast and replay will …

Baxter International (BAX) Surpasses Q2 Earnings and Revenue Estimates

Baxter International (BAX) reported strong Q2 earnings of $0.56 per share, significantly beating the Zacks Consensus Estimate of $0.36, and exceeded revenue expectations with $2.96 billion. Despite this positive performance, the company currently holds a Zacks Rank #4 (Sell) due to unfavorable estimate revisions. …

Aptar Reports Second Quarter 2026 Results

AptarGroup, Inc. reported its second quarter 2026 results, highlighting a 6% increase in reported sales to over $1 billion for the first time. The company saw revenue growth across all three segments, with Aptar Pharma leading the way, and returned $81 million to shareholders …